PTGX vs. GLPG, KROS, EVO, ARDX, AGIO, CPRX, SNDX, NAMS, ZLAB, and RCKT
Should you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Galapagos (GLPG), Keros Therapeutics (KROS), Evotec (EVO), Ardelyx (ARDX), Agios Pharmaceuticals (AGIO), Catalyst Pharmaceuticals (CPRX), Syndax Pharmaceuticals (SNDX), NewAmsterdam Pharma (NAMS), Zai Lab (ZLAB), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.
Galapagos currently has a consensus price target of $34.50, indicating a potential upside of 26.88%. Protagonist Therapeutics has a consensus price target of $38.00, indicating a potential upside of 26.75%. Given Protagonist Therapeutics' higher probable upside, analysts plainly believe Galapagos is more favorable than Protagonist Therapeutics.
32.5% of Galapagos shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Galapagos has higher revenue and earnings than Protagonist Therapeutics.
Galapagos has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500.
In the previous week, Protagonist Therapeutics had 2 more articles in the media than Galapagos. MarketBeat recorded 7 mentions for Protagonist Therapeutics and 5 mentions for Galapagos. Galapagos' average media sentiment score of 1.17 beat Protagonist Therapeutics' score of 0.26 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Galapagos received 205 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 64.54% of users gave Galapagos an outperform vote while only 59.73% of users gave Protagonist Therapeutics an outperform vote.
Protagonist Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -26.25%. Galapagos' return on equity of 43.42% beat Protagonist Therapeutics' return on equity.
Summary
Protagonist Therapeutics beats Galapagos on 11 of the 16 factors compared between the two stocks.
Get Protagonist Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protagonist Therapeutics Competitors List
Related Companies and Tools
